Clinical Evaluation of Healthy Subjects Receiving Intradermal Saline Using the Microneedle Adapter (Model UAR-2S)

Microdermics Inc. is a British Columbia-based Canadian incorporation primarily focusing on microneedle-based painless and effective drug delivery systems.The Microneedle Adapter (model UAR-2S) is a single-use disposable medical device intended to provide a mechanism for intradermal bolus fluid delivery when used with a standard syringe with a Luer-lock tip connection. The Microneedle Adapter consists of a single-use gold-coated metallic microneedle integrated within the microneedle adapter with fluidic connections to a standard Luer syringe mount. The primary function of the Microneedle Adapter is to guide the microneedle into the skin in a controlled manner for successful insertion passing the stratum corneum layer. The fluid loaded onto the syringe can then be injected precisely intradermally into the skin.The primary objective of this study is to evaluate the performance of the Microneedle Adapter in healthy subjects in 3 different injection sites. Pain perception of the Microneedle Adapter will be a key secondary outcome, compared with the control device.

Study Overview

• Status: Completed
• Conditions: Intradermal Injection
• Intervention / Treatment: Device: Microneedle Adapter (Model UAR-2S); Device: Hypodermic needle + syringe

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Québec City, Quebec, Canada, G1P 0A2
      • inVentiv Health Clinique

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy male or female, 19-65 years old inclusive, non-smoker (no use of tobacco products within 3 months prior to screening)
2. Able to understand the informed consent form and willing to participate in study
3. Intact skin at the sites of injection

4. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive method throughout the study and for 30 days after the last study drug administration:

   1. intra-uterine contraceptive device placed at least 4 weeks prior to study drug administration;
   2. male condom with intravaginally applied spermicide starting at least 14 days prior to study drug administration;
   3. hormonal contraceptives starting at least 4 weeks prior to study drug administration and must agree to use the same hormonal contraceptive throughout the study;
   4. sterile male partner (vasectomized since at least 6 months).

Exclusion Criteria:

1. Fear or anxiety of needles, or needle phobia
2. Known sensitivity to nickel
3. Presence of a skin condition at the treatment are that may affect the configuration or thickness of the dermal layer (e.g. plaque psoriasis)
4. Permanent makeup/tattoo/body piercing or other markings in the treatment area that would impact the ability to assess adverse events (e.g. erythema) following ID administration
5. Use of medication that may affect the mechanical properties of the skin in the treatment area (e.g. prolonged use of a steroids, analgesics or other non-steroidal inflammatory drugs)
6. Any implantable metal device in the treatment area
7. Any surgical procedure, or other invasive or non-invasive method of skin therapy hair removal or filers or Botox in the treatment area, performed in the past 1 months (in the treatment area).
8. Any form of suspicious lesion on the treatment area
9. Hypertrophic scarring, keloids, abnormal wound healing, as well as very dry and fragile skin.
10. Any infection/abscess/pain in treatment area
11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash
12. History of skin allergy or hypersensitivity
13. History of easy bruising
14. Actively taking antibiotics for an infection
15. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
16. Any other condition that would exclude the subject study participation according to the Investigator's clinical judgment
17. Concurrent participation in any other clinical study
18. Unable to understand the informed consent
19. Unable to verbally communicate in English or French
20. If female, pregnant, suspected or planning to become pregnant or breast-feeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Intervention arm; Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).

Device: Microneedle Adapter (Model UAR-2S); Investigational device; Device: Hypodermic needle + syringe; Control device

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the performance of the Microneedle Adapter in the inner forearm	Consistency of injected fluid volume by gravimetric technique	1 day
Evaluate the performance of the Microneedle Adapter in the deltoid	Consistency of injected fluid volume by gravimetric technique	1 day
Evaluate the performance of the Microneedle Adapter in the thigh	Consistency of injected fluid volume by gravimetric technique	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate pain perception of the Microneedle Adapter vs. the control device	Assessment of pain intensity using Numeric Rating Scale (NRS), a verbal 0-10 point scale where 0 means no pain and 10 means worst possible pain	1 day (post needle injection and post fluid injection)
Collection and evaluation of adverse events [safety and tolerability]	Events will be reported by severity and causality	2 weeks
Assessment of contact dermatitis using Draize Scale [safety and tolerability]	Draize scale has 4 components (Hemorrhage/petechiae, Erythema, Edema, Pruritus) with scores 0 up to 5, where 5 indicates worst event	2 weeks
Assess end-user satisfaction in using the Microneedle Adapter and obtain feedback on the device's design	Assessment of end-user usability using the modified System Usability Scale (mSUS), a 10-question scale producing a normalized score 0 to 100, where 0 indicates high user dissatisfaction and 100 indicates high user satisfaction	2 weeks

Collaborators and Investigators

• Sponsor: Microdermics Inc.
• Investigators: Principal Investigator: Richard Larouche, MD, inVentiv Health Clinique

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2017
• Primary Completion (Actual): November 15, 2017
• Study Completion (Actual): November 15, 2017

Study Registration Dates

• First Submitted: January 18, 2018
• First Submitted That Met QC Criteria: January 23, 2018
• First Posted (Actual): January 30, 2018

Study Record Updates

• Last Update Posted (Actual): January 30, 2018
• Last Update Submitted That Met QC Criteria: January 23, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: UAR-CLIN-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No